Leerink Swann reiterated their positive rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report sent to investors on Wednesday, The Fly reports. The brokerage currently has a $29.00 price objective on the stock, up from their previous price objective of $20.00.
A number of other research analysts have also recently commented on DCPH. Cantor Fitzgerald increased their target price on Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the company an overweight rating in a research note on Wednesday. ValuEngine cut Deciphera Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. Guggenheim increased their target price on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a buy rating in a research note on Tuesday. Zacks Investment Research raised Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 target price on the stock in a research note on Monday, August 5th. Finally, Piper Jaffray Companies increased their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an overweight rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Deciphera Pharmaceuticals has a consensus rating of Buy and an average target price of $47.90.
DCPH traded down $1.83 during trading on Wednesday, reaching $36.04. The stock had a trading volume of 248,128 shares, compared to its average volume of 331,819. The stock has a market capitalization of $762.39 million, a PE ratio of -12.80 and a beta of 2.34. The company has a current ratio of 7.26, a quick ratio of 7.26 and a debt-to-equity ratio of 0.01. Deciphera Pharmaceuticals has a one year low of $18.55 and a one year high of $42.99. The firm’s 50-day moving average is $22.85.
In other news, Director Michael Douglas Taylor sold 22,500 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $40.77, for a total transaction of $917,325.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Thomas Patrick Kelly sold 2,100 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $25.20, for a total value of $52,920.00. The disclosure for this sale can be found here. Insiders have sold 185,607 shares of company stock worth $7,536,409 over the last ninety days. Insiders own 7.02% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Bank of Montreal Can purchased a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth about $28,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after purchasing an additional 1,831 shares during the period. Tower Research Capital LLC TRC purchased a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth about $64,000. JPMorgan Chase & Co. boosted its holdings in shares of Deciphera Pharmaceuticals by 89.2% during the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after purchasing an additional 1,913 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of Deciphera Pharmaceuticals by 214.8% during the second quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after purchasing an additional 5,366 shares during the period. 59.10% of the stock is currently owned by hedge funds and other institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: Bid-Ask Spread
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.